RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model

Abstract This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2 b mice in a 30–40% humidified environment together with daily scopolamine hydrobromide...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chae Eun Kim, Hynda K. Kleinman, Gabriel Sosne, George W Ousler, Kyeongsoon Kim, Sinwook Kang, Jaewook Yang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/209b22d9f1ca4439aacdcb974310bacf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:209b22d9f1ca4439aacdcb974310bacf
record_format	dspace
spelling	oai:doaj.org-article:209b22d9f1ca4439aacdcb974310bacf2021-12-02T15:08:27ZRGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model10.1038/s41598-018-28861-52045-2322https://doaj.org/article/209b22d9f1ca4439aacdcb974310bacf2018-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-28861-5https://doaj.org/toc/2045-2322Abstract This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2 b mice in a 30–40% humidified environment together with daily scopolamine hydrobromide injections for 10 days. After desiccation stress, all drugs were evaluated after 10 treatment days. RGN-259 increased tear production similar to that in the DQS- and LFA-treated mice while CsA was inactive. RGN-259 improved corneal smoothness and decreased fluorescein staining similar to that of LFA group while CsA and DQS were inactive. Corneal epithelial detachment was reduced by RGN-259, and DQS and LFA showed similar activity but the CsA was inactive. RGN-259 increased conjunctival goblet cells and mucin production comparable to that seen with CsA, while DQS and LFA were inactive. RGN-259 reduced the over-expression of inflammatory factors comparable to that with CsA and LFA, while DQS was inactive. RGN-259 increased mucin production comparable to that observed with CsA, while DQS and LFA were inactive. In conclusion, RGN-259 promoted recovery of mucins and goblet cells, improved corneal integrity, and reduced inflammation in a dry eye mouse model and was equal to or more effective than prescription treatments.Chae Eun KimHynda K. KleinmanGabriel SosneGeorge W OuslerKyeongsoon KimSinwook KangJaewook YangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-14 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chae Eun Kim Hynda K. Kleinman Gabriel Sosne George W Ousler Kyeongsoon Kim Sinwook Kang Jaewook Yang RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
description	Abstract This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2 b mice in a 30–40% humidified environment together with daily scopolamine hydrobromide injections for 10 days. After desiccation stress, all drugs were evaluated after 10 treatment days. RGN-259 increased tear production similar to that in the DQS- and LFA-treated mice while CsA was inactive. RGN-259 improved corneal smoothness and decreased fluorescein staining similar to that of LFA group while CsA and DQS were inactive. Corneal epithelial detachment was reduced by RGN-259, and DQS and LFA showed similar activity but the CsA was inactive. RGN-259 increased conjunctival goblet cells and mucin production comparable to that seen with CsA, while DQS and LFA were inactive. RGN-259 reduced the over-expression of inflammatory factors comparable to that with CsA and LFA, while DQS was inactive. RGN-259 increased mucin production comparable to that observed with CsA, while DQS and LFA were inactive. In conclusion, RGN-259 promoted recovery of mucins and goblet cells, improved corneal integrity, and reduced inflammation in a dry eye mouse model and was equal to or more effective than prescription treatments.
format	article
author	Chae Eun Kim Hynda K. Kleinman Gabriel Sosne George W Ousler Kyeongsoon Kim Sinwook Kang Jaewook Yang
author_facet	Chae Eun Kim Hynda K. Kleinman Gabriel Sosne George W Ousler Kyeongsoon Kim Sinwook Kang Jaewook Yang
author_sort	Chae Eun Kim
title	RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
title_short	RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
title_full	RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
title_fullStr	RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
title_full_unstemmed	RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
title_sort	rgn-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/209b22d9f1ca4439aacdcb974310bacf
work_keys_str_mv	AT chaeeunkim rgn259thymosinb4improvesclinicallyimportantdryeyeefficaciesincomparisonwithprescriptiondrugsinadryeyemodel AT hyndakkleinman rgn259thymosinb4improvesclinicallyimportantdryeyeefficaciesincomparisonwithprescriptiondrugsinadryeyemodel AT gabrielsosne rgn259thymosinb4improvesclinicallyimportantdryeyeefficaciesincomparisonwithprescriptiondrugsinadryeyemodel AT georgewousler rgn259thymosinb4improvesclinicallyimportantdryeyeefficaciesincomparisonwithprescriptiondrugsinadryeyemodel AT kyeongsoonkim rgn259thymosinb4improvesclinicallyimportantdryeyeefficaciesincomparisonwithprescriptiondrugsinadryeyemodel AT sinwookkang rgn259thymosinb4improvesclinicallyimportantdryeyeefficaciesincomparisonwithprescriptiondrugsinadryeyemodel AT jaewookyang rgn259thymosinb4improvesclinicallyimportantdryeyeefficaciesincomparisonwithprescriptiondrugsinadryeyemodel
_version_	1718388110240251904

RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model

Ejemplares similares